We have achieved our First Patient In (FPI) milestone in the Phase II clinical study in patients with Non-Small Cell lunch Cancer (NSCLC). The clinical study is being conducted at 7 sites in Russia after the recent approval by the Ministry of Health of two additional sites.

Russia is a prominent recruiter for clinical studies involving patients with NSCLC with 147 million population. Lung cancer incidence in Russia is 71.6 per 100000 population with NSCLC taking approximately 75-80% of all lung cancers. Accell works with over 50 renowned clinical research sites specializing in oncology in Russia to deliver fast patient recruitment and high quality results.